Protocol Ledger

NCT03890120 · Phase III · TERMINATED

Study of Cilofexor in Adults With Primary Sclerosing Cholangitis

Interventional Phase III clinical trial protocol NCT03890120 sponsored by Gilead Sciences in Gastroenterology, Hepatology, and Renal, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-03-27 Enrollment: 419 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03890120
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)419 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03890120
Protocol FieldVerified Registry Value
NCT IdentifierNCT03890120
Consolidated Lead SponsorGilead Sciences
Therapeutic Condition CohortGastroenterology, Hepatology, and Renal
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment419 participants (ACTUAL)
Registered Start Date2019-03-27
WhyStopped ClassificationLack of Efficacy / Futility

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Gilead Sciences across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Gastroenterology, Hepatology, and Renal Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI